HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kupprion, C. Articles by Sage, E. H. Search for Related Content PubMed PubMed Citation Articles by Kupprion, C. Articles by Sage, E. H. Social Bookmarking                      What's this?

J Biol Chem, Vol. 273, Issue 45, 29635-29640, November 6, 1998

SPARC (BM-40, Osteonectin) Inhibits the Mitogenic Effect of Vascular Endothelial Growth Factor on Microvascular Endothelial Cells

From the Department of Biological Structure, University of Washington School of Medicine, Seattle, Washington 98195-7420

SPARC (secreted protein, acidic and rich in cysteine) is a matricellular protein that modulates cell adhesion and proliferation and is thought to function in tissue remodeling and angiogenesis. In this study, we demonstrate that SPARC inhibits DNA synthesis by >90% in human microvascular endothelial cells (HMEC) stimulated by the endothelial cell mitogen vascular endothelial growth factor (VEGF). Peptides derived from SPARC domain IV, which contains a disulfide-bonded EF-hand sequence and binds to endothelial cells, mimicked the effect of native SPARC. The inhibition was also observed with a peptide from the follistatin-like domain II, whereas peptides from SPARC domains I and III had no effect on VEGF-stimulated DNA synthesis. The inhibition of HMEC proliferation was mediated in part by the binding of VEGF to SPARC. The binding of ¹²⁵I-VEGF to HMEC was reduced by SPARC and SPARC peptides from domain IV in a concentration-dependent manner. In a radioimmune precipitation assay, peptides from SPARC domains II and IV each competed with native SPARC for its binding to VEGF. It has been reported that VEGF stimulates the tyrosine phosphorylation and activation of mitogen-activated protein kinases Erk1 and Erk2. We now show that SPARC reduces this phosphorylation in VEGF-stimulated HMEC to levels of unstimulated controls. SPARC thus modulates the mitogenic activity of VEGF through a direct binding interaction and reduces the association of VEGF with its cell-surface receptors. Moreover, an additional diminution of VEGF activity by SPARC is accomplished through a reduction in the tyrosine phosphorylation of mitogen-activated protein kinases.

CiteULike

Complore

Connotea

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				G. Rotta, G. Matteoli, E. Mazzini, P. Nuciforo, M. P. Colombo, and M. Rescigno Contrasting roles of SPARC-related granuloma in bacterial containment and in the induction of anti-Salmonella typhimurium immunity J. Exp. Med., March 17, 2008; 205(3): 657 - 667. [Abstract] [Full Text] [PDF]

				P. Liu, J. Lu, W. V. Cardoso, and C. Vaziri The SPARC-related Factor SMOC-2 Promotes Growth Factor-induced Cyclin D1 Expression and DNA Synthesis via Integrin-linked Kinase Mol. Biol. Cell, January 1, 2008; 19(1): 248 - 261. [Abstract] [Full Text] [PDF]

				N. Said, M. J. Socha, J. J. Olearczyk, A. A. Elmarakby, J. D. Imig, and K. Motamed Normalization of the Ovarian Cancer Microenvironment by SPARC Mol. Cancer Res., October 1, 2007; 5(10): 1015 - 1030. [Abstract] [Full Text] [PDF]

				E. F. Rocnik, P. Liu, K. Sato, K. Walsh, and C. Vaziri The Novel SPARC Family Member SMOC-2 Potentiates Angiogenic Growth Factor Activity J. Biol. Chem., August 11, 2006; 281(32): 22855 - 22864. [Abstract] [Full Text] [PDF]

				W. Wang, C. Mei, B. Tang, H. Zhao, C. Xu, Z. Li, X. Shen, W. Fu, and B. Dai Aberrant expression of SPARC and its impact on proliferation and apoptosis in ADPKD cyst-lining epithelia Nephrol. Dial. Transplant., May 1, 2006; 21(5): 1278 - 1288. [Abstract] [Full Text] [PDF]

				N. Said and K. Motamed Absence of Host-Secreted Protein Acidic and Rich in Cysteine (SPARC) Augments Peritoneal Ovarian Carcinomatosis Am. J. Pathol., December 1, 2005; 167(6): 1739 - 1752. [Abstract] [Full Text] [PDF]

				M. W.M. Schellings, Y. M. Pinto, and S. Heymans Matricellular proteins in the heart: possible role during stress and remodeling Cardiovasc Res, October 1, 2004; 64(1): 24 - 31. [Abstract] [Full Text] [PDF]

				H. T. Keutmann, A. L. Schneyer, and Y. Sidis The Role of Follistatin Domains in Follistatin Biological Action Mol. Endocrinol., January 1, 2004; 18(1): 228 - 240. [Abstract] [Full Text] [PDF]

				S. V. Vadlamuri, J. Media, S. S. Sankey, A. Nakeff, G. Divine, and S. A. Rempel SPARC affects glioma cell growth differently when grown on brain ECM proteins in vitro under standard versus reduced-serum stress conditions Neuro-oncol, October 1, 2003; 5(4): 244 - 254. [Abstract] [PDF]

				B. J. Schiemann, J. R. Neil, and W. P. Schiemann SPARC Inhibits Epithelial Cell Proliferation in Part through Stimulation of the Transforming Growth Factor-{beta}-Signaling System Mol. Biol. Cell, October 1, 2003; 14(10): 3977 - 3988. [Abstract] [Full Text] [PDF]

				E. H. Sage, M. Reed, S. E. Funk, T. Truong, M. Steadele, P. Puolakkainen, D. H. Maurice, and J. A. Bassuk Cleavage of the Matricellular Protein SPARC by Matrix Metalloproteinase 3 Produces Polypeptides That Influence Angiogenesis J. Biol. Chem., September 26, 2003; 278(39): 37849 - 37857. [Abstract] [Full Text] [PDF]

				A. Chlenski, S. Liu, S. E. Crawford, O. V. Volpert, G. H. DeVries, A. Evangelista, Q. Yang, H. R. Salwen, R. Farrer, J. Bray, et al. SPARC Is a Key Schwannian-derived Inhibitor Controlling Neuroblastoma Tumor Angiogenesis Cancer Res., December 15, 2002; 62(24): 7357 - 7363. [Abstract] [Full Text] [PDF]

				C. Schultz, N. Lemke, S. Ge, W. A. Golembieski, and S. A. Rempel Secreted Protein Acidic and Rich in Cysteine Promotes Glioma Invasion and Delays Tumor Growth in Vivo Cancer Res., November 1, 2002; 62(21): 6270 - 6277. [Abstract] [Full Text] [PDF]

				C. Vannahme, N. Smyth, N. Miosge, S. Gosling, C. Frie, M. Paulsson, P. Maurer, and U. Hartmann Characterization of SMOC-1, a Novel Modular Calcium-binding Protein in Basement Membranes J. Biol. Chem., October 4, 2002; 277(41): 37977 - 37986. [Abstract] [Full Text] [PDF]

				D.-H. Kang, J. Kanellis, C. Hugo, L. Truong, S. Anderson, D. Kerjaschki, G. F. Schreiner, and R. J. Johnson Role of the Microvascular Endothelium in Progressive Renal Disease J. Am. Soc. Nephrol., March 1, 2002; 13(3): 806 - 816. [Abstract] [Full Text] [PDF]

				Q. Yan, J. I. Clark, T. N. Wight, and E. H. Sage Alterations in the lens capsule contribute to cataractogenesis in SPARC-null mice J. Cell Sci., January 7, 2002; 115(13): 2747 - 2756. [Abstract] [Full Text] [PDF]

				A. D. Bradshaw, M. J. Reed, and E. H. Sage SPARC-null Mice Exhibit Accelerated Cutaneous Wound Closure J. Histochem. Cytochem., January 1, 2002; 50(1): 1 - 10. [Abstract] [Full Text] [PDF]

				G. K. Yiu, W. Y. Chan, S.-W. Ng, P. S. Chan, K. K. Cheung, R. S. Berkowitz, and S. C. Mok SPARC (Secreted Protein Acidic and Rich in Cysteine) Induces Apoptosis in Ovarian Cancer Cells Am. J. Pathol., August 1, 2001; 159(2): 609 - 622. [Abstract] [Full Text]

				A. Nishie, K. Masuda, M. Otsubo, T. Migita, M. Tsuneyoshi, K. Kohno, T. Shuin, S. Naito, M. Ono, and M. Kuwano High Expression of the Cap43 Gene in Infiltrating Macrophages of Human Renal Cell Carcinomas Clin. Cancer Res., July 1, 2001; 7(7): 2145 - 2151. [Abstract] [Full Text] [PDF]

				R. A. Brekken, J. P. Overholser, V. A. Stastny, J. Waltenberger, J. D. Minna, and P. E. Thorpe Selective Inhibition of Vascular Endothelial Growth Factor (VEGF) Receptor 2 (KDR/Flk-1) Activity by a Monoclonal Anti-VEGF Antibody Blocks Tumor Growth in Mice Cancer Res., September 1, 2000; 60(18): 5117 - 5124. [Abstract] [Full Text]

				R. Thomas, L. D. True, J. A. Bassuk, P. H. Lange, and R. L. Vessella Differential Expression of Osteonectin/SPARC during Human Prostate Cancer Progression Clin. Cancer Res., March 1, 2000; 6(3): 1140 - 1149. [Abstract] [Full Text]

				Q. Yan and E. H. Sage SPARC, a Matricellular Glycoprotein with Important Biological Functions J. Histochem. Cytochem., December 1, 1999; 47(12): 1495 - 1506. [Full Text]

				A. Francki, A. D. Bradshaw, J. A. Bassuk, C. C. Howe, W. G. Couser, and E. H. Sage SPARC Regulates the Expression of Collagen Type I and Transforming Growth Factor-beta 1 in Mesangial Cells J. Biol. Chem., November 5, 1999; 274(45): 32145 - 32152. [Abstract] [Full Text] [PDF]

				A. D. Bradshaw, A. Francki, K. Motamed, C. Howe, and E. H. Sage Primary Mesenchymal Cells Isolated from SPARC-null Mice Exhibit Altered Morphology and Rates of Proliferation Mol. Biol. Cell, May 1, 1999; 10(5): 1569 - 1579. [Abstract] [Full Text]

				K. Tsuchida, K. Y. Arai, Y. Kuramoto, N. Yamakawa, Y. Hasegawa, and H. Sugino Identification and Characterization of a Novel Follistatin-like Protein as a Binding Protein for the TGF-beta Family J. Biol. Chem., December 22, 2000; 275(52): 40788 - 40796. [Abstract] [Full Text] [PDF]

				Y. Sidis, A. L. Schneyer, P. M. Sluss, L. N. Johnson, and H. T. Keutmann Follistatin: Essential Role for the N-terminal Domain in Activin Binding and Neutralization J. Biol. Chem., May 18, 2001; 276(21): 17718 - 17726. [Abstract] [Full Text] [PDF]